EWTX fundamentals
An in-depth look to Edgewise Therapeutics, Inc. operating, investing, and financing activities
EWTX free cash flow for Q4 23 is -26.99 M USD. For 2023, EWTX free cash flow was -97.69 M USD and operating cash flow was -91.95 M USD.
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
TTM